Clinical Trial: Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07501650) titled 'Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer' on March 24.

Brief Summary: This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab) among patients with R/M HNSCC, delivered with ultrasound-induced microbubble cavitation, with the goal of optimizing delivery of Pembrolizumab and tumor response to Pembrolizumab. Patients will undergo 3 infusions of Pembrolizumab plus Definity 3 weeks apart. Following each infusion, ultrasound will be directed at the primary tumor site to induce microbubble cavitation, with the goal of tumor sonoporation. The primary endpoints will be feasibility, m...